Lineage Distribution Using Whole-Genome Sequencing and Bedaquiline, Clofazimine, and Linezolid Phenotypic Profiles Among Rifampicin-Resistant Isolates from West Java, Indonesia

Overview

Journal Int J Microbiol

Publisher Wiley

Specialty Microbiology

Date 2024 Mar 12

PMID 38469390

Authors

Andriansjah Rukmana

Cynthia Gozali

Linda Erlina

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) is caused by infection. Indonesia is ranked second in the world for TB cases. New anti-TB drugs from groups A and B, such as bedaquiline, clofazimine, and linezolid, have been shown to be effective in curing drug resistance in TB patients, and Indonesia is already using these drugs to treat patients. However, studies comparing the TB strain types with anti-TB resistance profiles are still relevant to understanding the prevalent strains in the country and their phenotypic characteristics. This study aimed to determine the association between the TB lineage distribution using whole-genome sequencing and bedaquiline, clofazimine, and linezolid phenotypic profile resistance among rifampicin-resistant isolates from West Java. isolates stock of the Department of Microbiology, Faculty of Medicine, Universitas Indonesia, was tested against bedaquiline, clofazimine, and linezolid using a mycobacteria growth indicator tube liquid culture. All isolates were tested for and rifampicin resistance using Xpert MTB/RIF. The DNA genome of was freshly extracted from a Löwenstein-Jensen medium culture and then sequenced. The isolates showed phenotypically resistance to bedaquiline, clofazimine, and linezolid at 5%, 0%, and 0%, respectively. We identified gene mutations on phenotypically bedaquiline-resistant strains (2/3), and other mutations also found in phenotypically drug-sensitive strains. Mykrobe analysis showed that most (88.33%) of the isolates could be classified as rifampicin-resistant TB. Using Mykrobe and TB-Profiler to determine the lineage distribution, the isolates were found to belong to lineage 4 (Euro-American; 48.33%), lineage 2 (East Asian/Beijing; 46.67%), and lineage 1 (Indo-Oceanic; 5%). This work underlines the requirement to increase the representation of genotype-phenotype TB data while also highlighting the importance and efficacy of WGS in predicting medication resistance and inferring disease transmission.

Citing Articles

Comprehensive genomic surveillance reveals transmission profiles of extensively drug-resistant tuberculosis cases in Pará, Brazil.

Marcon D, Sharma A, Souza A, Barros R, Andrade V, Guimaraes R Front Microbiol. 2025; 15:1514862.

PMID: 39911713 PMC: 11794272. DOI: 10.3389/fmicb.2024.1514862.

References

Espinosa-Pereiro J, Sanchez-Montalva A, Aznar M, Espiau M . MDR Tuberculosis Treatment. Medicina (Kaunas). 2022; 58(2). PMC: 8878254. DOI: 10.3390/medicina58020188. View

Hunt M, Bradley P, Grandjean Lapierre S, Heys S, Thomsit M, Hall M . Antibiotic resistance prediction for from genome sequence data with Mykrobe. Wellcome Open Res. 2020; 4:191. PMC: 7004237. DOI: 10.12688/wellcomeopenres.15603.1. View

Rafael L, Raquel M, Rogelio F, Miroslava F, Alejandra-Isabel J, Paola R . Discordant results between genotypic and phenotypic assays (Xpert MTB/RIF vs. BACTEC MGIT 960 system) for detection of RIF-resistant Mycobacterium tuberculosis isolates in a high burden region. Infect Genet Evol. 2021; 96:105142. DOI: 10.1016/j.meegid.2021.105142. View

Phyu A, Aung S, Palittapongarnpim P, Htet K, Mahasirimongkol S, Aung H . Distribution of Lineages and Drug Resistance in Upper Myanmar. Trop Med Infect Dis. 2022; 7(12). PMC: 9781755. DOI: 10.3390/tropicalmed7120448. View

Park S, Jung J, Kim J, Han S, Ryoo S . Investigation of Clofazimine Resistance and Genetic Mutations in Drug-Resistant Isolates. J Clin Med. 2022; 11(7). PMC: 9000149. DOI: 10.3390/jcm11071927. View

Holt K, McAdam P, Thai P, Thuong N, Ha D, Lan N . Frequent transmission of the Mycobacterium tuberculosis Beijing lineage and positive selection for the EsxW Beijing variant in Vietnam. Nat Genet. 2018; 50(6):849-856. PMC: 6143168. DOI: 10.1038/s41588-018-0117-9. View

Peker N, Schuele L, Kok N, Terrazos M, Neuenschwander S, de Beer J . Evaluation of whole-genome sequence data analysis approaches for short- and long-read sequencing of . Microb Genom. 2021; 7(11). PMC: 8743536. DOI: 10.1099/mgen.0.000695. View

Phelan J, OSullivan D, Machado D, Ramos J, Oppong Y, Campino S . Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. Genome Med. 2019; 11(1):41. PMC: 6591855. DOI: 10.1186/s13073-019-0650-x. View

Diriba G, Kebede A, Tola H, Alemu A, Yenew B, Moga S . Mycobacterial Lineages Associated with Drug Resistance in Patients with Extrapulmonary Tuberculosis in Addis Ababa, Ethiopia. Tuberc Res Treat. 2021; 2021:5239529. PMC: 8476284. DOI: 10.1155/2021/5239529. View

10.

Guo Q, Bi J, Lin Q, Ye T, Wang Z, Wang Z . Whole Genome Sequencing Identifies Novel Mutations Associated With Bedaquiline Resistance in . Front Cell Infect Microbiol. 2022; 12:807095. PMC: 9184757. DOI: 10.3389/fcimb.2022.807095. View

11.

Nahid P, Mase S, Migliori G, Sotgiu G, Bothamley G, Brozek J . Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019; 200(10):e93-e142. PMC: 6857485. DOI: 10.1164/rccm.201909-1874ST. View

12.

Crossley B, Bai J, Glaser A, Maes R, Porter E, Killian M . Guidelines for Sanger sequencing and molecular assay monitoring. J Vet Diagn Invest. 2020; 32(6):767-775. PMC: 7649556. DOI: 10.1177/1040638720905833. View

13.

Wu S, Chan H, Hsiao H, Jou R . Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan. Front Microbiol. 2021; 12:754249. PMC: 8569445. DOI: 10.3389/fmicb.2021.754249. View

14.

Mesfin E, Merker M, Beyene D, Tesfaye A, Shuaib Y, Addise D . Prediction of drug resistance by Sanger sequencing of Mycobacterium tuberculosis complex strains isolated from multidrug resistant tuberculosis suspect patients in Ethiopia. PLoS One. 2022; 17(8):e0271508. PMC: 9355188. DOI: 10.1371/journal.pone.0271508. View

15.

Brankin A, Seifert M, Georghiou S, Walker T, Uplekar S, Suresh A . In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis. Sci Rep. 2022; 12(1):17741. PMC: 9587982. DOI: 10.1038/s41598-022-21025-6. View

16.

Nebenzahl-Guimaraes H, Yimer S, Holm-Hansen C, de Beer J, Brosch R, van Soolingen D . Genomic characterization of lineage 7 and a proposed name: 'Aethiops vetus'. Microb Genom. 2017; 2(6):e000063. PMC: 5320646. DOI: 10.1099/mgen.0.000063. View

17.

Kaniga K, Hasan R, Jou R, Vasiliauskiene E, Chuchottaworn C, Ismail N . Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates. J Clin Microbiol. 2021; 60(1):e0291920. PMC: 8769720. DOI: 10.1128/JCM.02919-20. View

18.

Micheni L, Kassaza K, Kinyi H, Ntulume I, Bazira J . Diversity of Complex Lineages Associated with Pulmonary Tuberculosis in Southwestern, Uganda. Tuberc Res Treat. 2021; 2021:5588339. PMC: 8264515. DOI: 10.1155/2021/5588339. View

19.

Dookie N, Khan A, Padayatchi N, Naidoo K . Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field. Front Microbiol. 2022; 13:775030. PMC: 8988194. DOI: 10.3389/fmicb.2022.775030. View

20.

Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L . Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One. 2014; 9(7):e102135. PMC: 4092087. DOI: 10.1371/journal.pone.0102135. View